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Abstract 
 
Immune responses contribute to the success of radiation therapy of solid tumors; 
however, the mechanism of triggering CD8
+
 T cell responses is poorly understood. 
Antigen cross-presentation from tumor cells by dendritic cells (DC) is a likely 
dominant mechanism to achieve CD8
+
 T cell stimulation. We established a cross-
presentation model in prostate cancer in which DC present a naturally expressed 
oncofoetal tumor antigen (5T4) from irradiated DU145 tumor cells to 5T4-specific T 
cells. Ionising radiation (12 Gy) caused G2/M cell cycle arrest and cell death, 
increased cellular 5T4 and high-mobility protein group-B1 (HMGB1) levels and 
upregulated surface calreticulin and Hsp70 expression in DU145 cells. Co-culture of 
DC with irradiated tumor cells lead to efficient phagocytosis of tumor cells and 
upregulation of CD86 and HLA-DR on DC. CD8
+
 5T4-specific T cells, stimulated 
with these DC, proliferated and produced IFNγ. Inhibition of HMGB1 decreased T 
cell stimulation but not DC activation, while TRIF/MyD88 inhibition only had a 
marginal effect on T cell stimulation. Unlike previous reports, we found no functional 
evidence that DC with Asp299Gly toll-like receptor-4 (TLR4) single nucleotide 
polymorphism had impaired ability to cross-present tumor antigen. However, we 
observed a highly significant and robust prevention of antigen cross-presentation 
when tumor cells were pre-treated with the novel Hsp70 inhibitor, VER155008. The 
inhibitor also prevented CD86 upregulation on DC co-cultured with irradiated tumor 
cells. Together, our study demonstrates that radiation induces immunologically 
relevant changes in tumor cells, which can trigger CD8
+
 T cell responses via a 
predominantly Hsp70-dependent antigen cross-presentation process.  
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Introduction 
 Traditional treatments of cancer such as surgery, chemotherapy and 
radiotherapy (RT) have been shown to trigger immune responses, which may 
contribute towards treatment outcome. Radiation is curative in up to 40% of patients 
with early stage (localized) prostate cancer (PCa) but it is yet unclear what the 
predictors of complete responses are. RT in PCa has been shown to be associated with 
increased frequencies of tumor antigen-specific CD8
+
 and CD4
+
 T cells (1). The 
abscopal effect of radiation (tumor regression at a distant site following localized 
radiation) has been shown to be immune-mediated as demonstrated not only in mouse 
tumor models (2, 3) but also in patients with metastatic melanoma and lung 
adenocarcinoma (4, 5). Furthermore, CD8
+
 T cell infiltration in the irradiated tumor 
tissue serves as a prognostic factor (4-8) indicating that radiation can switch the 
immunosuppressive tumor milieu to a pro-immune environment. 
 For solid tumors, tumor antigen-specific CD8
+
 T cell responses can be induced 
either by tumor cells entering lymph nodes and presenting antigens directly (9) or by 
denriti cells (DC) cross-presenting tumor antigens, either in the lymph node or in 
ectopic lymphoid tissues, as observed in melanoma (10, 11). Efficient cross-
presentation requires tumor cell damage or cell death, associated with upregulation 
and/or release of danger signals or damage associated molecular patterns (DAMP). 
The precise nature of immunogenic cell death (ICD) is not well defined but generally 
involves surface translocation of “eat me” signals such as calreticulin (CRT) and 
stress-associated proteins such as Hsp70, release of chemoattractant molecules such 
as ATP and DAMP such as high-mobility protein group-B1 (HMGB1). However, 
there seems to be considerable plasticity in the combination and extent of these 
changes. The type of trigger causing cell damage and cell death may influence the 
relative proportions of key ICD events (12). Our study focuses on ionising radiation, 
which is known to cause DNA damage, cell cycle arrest and cellular damage response 
triggering either DNA repair or cellular senescence and apoptotic, necrotic or 
necroptotic cell death. Irradiated cells initiate post-phagocytic immune responses (13). 
The early release of IFNα/β by irradiated tumor cells can polarize antigen-presenting 
cells and aids their cross-presentation function (14). High dose (10-100 Gy) in vitro 
radiation of human tumor cells enhances CRT translocation to the cell surface and 
dose-dependent release of HMGB1 and ATP by breast, colon and prostate cancer cell 
lines (15). These typical ICD markers facilitate phagocytosis of damaged/dead cells 
and provide maturation signals for DC. Hsp70 translocation and release are also well-
documented consequences of radiation contributing to radiation resistance (16) with 
potential immunological effects (17).  
 The aim of our study was to determine the mechanism of radiation-mediated 
antigen cross-presentation in PCa. As antigen cross-presentation studies often use 
artificially overexpressed antigens which may provide false positive results, we 
established a model focussing on a naturally expressed oncofoetal antigen, 5T4 (18), 
which is expressed in most solid tumors, including PCa. The cross-presentation model 
we established enabled us to study the effect of irradiated tumor cells on DC 
phenotypic and functional maturation and the use of specific inhibitors to reveal the 
mechanism of the cross-presentation process. We show here that unlike in cross-
presentation induced by anthracyclines (19), in radiation-induced tumor antigen cross-
presentation the toll-like receptor-4 (TLR4) agonist-triggered TRIF/MyD88 pathway 
(20) plays only a partial role and the Asp299Gly TLR4 single nucleotide 
polymorphism (SNP) is not associated with any impairment of CD8
+
 T cell responses. 
Instead, we found that Hsp70 is crucially important both in activating DC and 
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triggering CD8
+
 T cell responses via DC co-cultured with irradiated tumor cells. Our 
results highlight the plasticity of the tumor antigen cross-presentation process and 
demonstrate the important immunological role of Hsp70 following tumor radiation. 
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Materials and Methods 
 
Media and Reagents 
 RPMI 1640 (Lonza, UK) was supplemented  with low endotoxin fetal bovine 
serum (FBS, PAA Laboratories, Austria) 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine (all from Gibco, UK), 25 mM Hepes buffer and 1 
mM sodium pyruvate (both Sigma, UK). 1% AB-serum (Sigma) was added where 
indicated. LPS and Glycyrrhizin were obtained from Sigma, VER155008 from Tocris 
Bioscience (R&D Systems, UK), MyD88 inhibitory peptide (and control) from 
ProImmune (Oxford, UK) and TRIF inhibitory peptide (and control) from Invivogen 
(San Diego, CA). 
 
Tumor cells and irradiation 
 DU145 human prostate cancer cells were obtained from ECACC and 
maintained in adherent cultures with regular passaging following trypsinization for 
less than 6 months. The cell line was authenticated by the supplier using cytogenetic, 
isoenzymatic and DNA profile analyzes. HLA typing results show that DU145 cells 
are HLA-A2
-
 (and encode for HLA-A03, A33, B50, B57) (Welsh Blood Transfusion 
Service, Cardiff). The cells were mycoplasma-free, as tested monthly using a 
MycoAlert Mycoplasma Detection Kit (Lonza). Cells used for experiments were in 
exponential phase of growth. Irradiation was carried out using a 
137
Cs-source (with 
dosimetry quality assurance) at a rate of 0.627 Gy/min.     
 
Donors, dendritic cell preparation 
 Ethical approval was granted for the study and informed consent was obtained 
from healthy volunteer donors. HLA Class I and II DNA typing was carried out as 
above. PBMC from venous blood collected in EDTA vacutainers was prepared by 
density gradient centrifugation. CD14
+
 monocytes were isolated by negative selection 
using the EasySep Human Monocyte Enrichment Kit without CD16 Depletion (Stem 
Cell Technologies, Grenoble, France) according to the manufacturer’s protocol. The 
average purity of CD14
+
 cells was 70-80%. The isolated cells were incubated at 5x10
6
 
cells/well in a 6 well tray and grown in 5ml/well in 10% FBS-RPMI in the presence 
of 500 ng/ml human recombinant (hr) GM-CSF (ProSpec, Israel) and 500 U/ml hr IL-
4 (Gentaur, Belgium) for 5-6 days.  
 
T cell and B cell line  
 A CD8
+
 T-cell line was developed from a HLA-A2
+
 healthy donor by repeated 
stimulation of non-adherent PBMC with autologous DC, loaded with 2 µg/ml 5T417-25 
peptide (RLARLALVL; 90.4% purity; ProImmune), as described previously (21). For 
the experiments, T-cells (1–2×10
6
) were expanded using a mixture of 5×10
6
 peptide-
pulsed autologous B lymphoblastoid cells (BLCL) irradiated with 40 Gy; 5×10
7
 
allogeneic PBMC mixed from 2 to 3 donors and irradiated with 30 Gy; 50 U/ml IL-2 
and 1 µl/ml OKT3 hybridoma supernatant (MRC Cooperative, Cardiff University) in 
50 ml RPMI supplemented as described above and with 10% FBS and 1% AB-serum 
in a T75 tissue culture flask (21). BLCL was developed from the same donor using 
EBV transformation of B cells from PBMC, following standard protocols.  
 
Immunocytochemistry 
 DU145 cells were grown on coverslips and incubated for 72h after 0Gy or 
12Gy radiation. They were fixed with acetone/methanol 1:1 (vol/vol) and labeled with 
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FITC-conjugated Hsp70 antibody (Enzo Life Sciences, Farmingdale, NY). The slides 
were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) and visualized next 
day using an Axiovert 40 fluorescence microscope (Zeiss, Jena, Germany). 
Flow cytometry 
 Cells (1-2x10
5
/sample) in 100 µl flow cytometry buffer (PBS, 1 mM EDTA 
and 2% FBS) were labeled with fluorochrome-conjugated 5T4, CRT, HMGB1 (R&D 
Systems), Hsp70 (Enzo Life Sciences), TLR-4, HLA-DR, CD86 and CD83 (E-
Bioscience) antibodies and incubated on ice for 40 min. For intracellular labelling the 
cells were fixed and permeabilized with E-Biosciences Fix/Perm reagents before 
antibodies were added for 40 min incubation at room temperature. For cytokine flow 
cytometry, T cells were fixed and permeabilized as above, and CD3, CD8 and IFNγ 
antibodies were added together to the cells for 40 min. Flow cytometry was carried 
out using a FACSCanto flow cytometer with FACSDiva software (Becton Dickinson 
Biosciences, Franklin Lakes, NJ).   
Inhibition of TRIF, MyD88, HMGB1 and Hsp70 
 The MyD88 and TRIF inhibitory peptides correspond to the sequence of the 
BB-loop of MyD88 (RDVLPGT) and TRIF (FCEEFQVPGRGELH), respectively, 
and serve as decoys by binding to the TIR domains and interfering with TLR-adaptor 
interactions (22, 23). The peptides are linked to protein transduction sequences, which 
render the peptides cell permeable. The control peptides consist of the protein 
transduction sequence alone. DC were pre-treated with 20 µM MyD88 inhibitory or 
control peptide or 10 µM TRIF inhibitory or control peptide, respectively, for 6h 
before adding DC to the irradiated or non-irradiated DU145 cells as described in the 
method for the cross-presentation assay. 
 Glycyrrhizin acid, an inhibitor for HMGB1, was added at 50 µM at the time of 
irradiation, while VER155008, an inhibitor for Hsp70, at 5 µM to 0Gy and 12Gy 
irradiated DU145 cells at 0h, 24h and 48h of the 72h incubation, respectively, as 
described in the method for the cross-presentation assay.    
 
Antigen cross-presentation 
 DU145 cells were set up into two 96 well U-bottom plates at 5x10
3
 cells/well. 
After an overnight incubation, one plate was irradiated with 12Gy prior to incubation 
for 72h at 37
o
C in 5% CO2. DC were then added to the wells with tumor cells at a 1:1 
ratio. The co-cultured cells were re-suspended and incubated for 48h after which 5T4 
specific T cells were added at a 1:1:5 (tumor cell:DC:T cell) ratio. Golgi Plug 
(0.5µl/500ml) and Golgi Stop (0.35µl/500ml) (both from Sigma) were added to the 
wells 1h later and the cultures were incubated overnight. Cytokine flow cytometry 
was carried out to determine the percentage of CD8
+
 T cells producing IFNγ in 
response to the antigen presented by DC. 
  
T cell proliferation in response to cross-presented antigen 
 DU145 cells were plated out in triplicates in two 24 well plates at 
1x10
5
cells/well in 1.5 ml. One plate was irradiated with 12Gy prior to incubation for 
72h. DC at 1x10
5
 cells/well in 0.5 ml were added per well to the tumor cells. After 4h, 
CSFE labelled T cells (5x10
5
cells/well) were added to the DC:tumor cell co-culture 
and the plates were incubated at an angle for 48h after which they were laid flat. After 
5 days of tumor cell:DC:T cell incubation, the cells were re-suspended and surface 
stained with CD3 and CD8-antibodies for flow cytometry analysis of CFSE dilution.  
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Single nucleotide polymorphism analysis 
 SNP analysis was carried out by the Department of Medical Genetics (Cardiff 
and Vale NHS Trust, University Hospital of Wales, Cardiff). The method comprises 
of DNA amplification from blood or established BLCL by PCR followed by 
pyrosequencing. The SNP analysis was optimised for the Asp299Gly sequence of the 
TLR4 polymorphism. Out of 67 samples tested, 4 donors were found to carry the 
Asp299Gly SNP.  
 
Statistical analysis  
 Statistical analysis was carried out by applying Student’s t-test, paired t-test 
and ANOVA with Tukey’s post-hoc test (GraphPad InStat 3.06). Significant 
differences are marked as *p<0.05, **p<0.01; ***p<0.001. 
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Results  
 
Irradiation induces immunologically relevant changes in tumor cells 
 Ionizing radiation causes DNA damage in individual cells and tissue damage 
in the tumor environment, the result of which maybe a pro-inflammatory immune 
reaction. To establish the optimum minimal radiation dose and incubation time which 
cause significant changes in DU145 PCa cells in vitro, dose escalation and time-
kinetics experiments were carried out. Cell cycle changes were measured by flow 
cytometry. There was a highly significant arrest in the G2/M phase in the irradiated 
cells, detectable at 24h post-radiation and remaining stable at 48h. There was a small 
but significant radiation dose-dependent increase at 48h in the proportion of cells in 
sub-G0 phase representing apoptotic cells with fragmented DNA (Fig. 1A). The type 
of cell death detected with Annexin/Propidium iodide (PI) labeling was mainly late 
apoptotic/necrotic and the proportion of cells with early apoptotic markers remained 
low throughout the incubation period (Fig. 1B). Other irradiation-associated, 
immunologically relevant changes were also observed. Surface MHC Class-I 
expression was not altered by radiation (not shown) but the cellular content of the 
target antigen 5T4 was significantly elevated following 12Gy radiation (Fig. 1C). The 
total cellular HMGB1 content was also measured by flow cytometry and a significant 
increase was observed, with early time kinetics (Fig. 1D). Hsp70 expression was 
strongly upregulated in the cytosol and on the cell surface by irradiation (Fig. 1E) as 
imaged at 72h post-irradiation. Multicolor flow cytometry analysis confirmed that 
upon irradiation the proportion of surface Hsp70 positive cells increased more than 
two-fold. CRT surface expression also increased more than 10-fold. Most CRT 
expressing cells were also positive for surface Hsp70 (Fig. 1F middle vs. right panel). 
These results demonstrate that radiation induces dramatic changes of numerous 
immunologically relevant parameters in tumor cells.  
 
Dendritic cell activation and tumor antigen cross-presentation following uptake 
of irradiated prostate cancer cells  
 Next we studied whether irradiated tumor cells are taken up by monocyte 
derived DC and whether this event can phenotypically activate DC and trigger their 
antigen presenting function. Tumor cells were irradiated with 12Gy and labelled with 
CFSE 72h later, when DC were added at 1:1 ratio. Phagocytosis was measured 24h 
later by determining the proportion of HLA-DR
+
CFSE
+
 cells. Although some tumor 
cell uptake (<5%) occurred when tumor cells were not irradiated (Fig. 2A i), the 
proportion of phagocytic DC increased significantly when encountering irradiated 
DU145 tumor cells (Fig. 2A ii and iii). DC phenotype following phagocytosis of 
irradiated or non-irradiated tumor cells was also studied 24h after DC-tumor cell co-
culture. CD86 and HLA-DR expression was significantly increased on DC that have 
encountered irradiated tumor cells compared to those that have been exposed to non-
irradiated tumor cells. The increase in CD83 expression was not significantly different 
in this donor (Fig. 2B), however, in repeated experiments with DC from other donors 
the difference was significant, leaving CD83 upregulation inconclusive.  
 In order to maximise irradiation-induced changes in tumor cells and tumor 
cell-uptake associated changes in DC before testing tumor antigen cross-presentation 
by the activation of 5T4-specific T cells, cross-presentation experiments were 
optimised and the method is described in detail in the Materials and Methods. Antigen 
cross-presentation from HLA-A2 negative tumor cells by HLA-A2
+
 DC was 
measured by the proliferation and intracellular cytokine production of a HLA-A2-
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restricted 5T4-peptide-specific T cell line (21). The T cell line can recognize naturally 
processed 5T4, as these T cells can kill 5T4
+
 HLA-A2
+
 tumor cells directly (21). 
Significant T cell proliferation was triggered by DC which were exposed to non-
irradiated DU145 cells, however T cell proliferation increased significantly compared 
to this, when DC co-cultured with irradiated DU145 cells were used to stimulate T 
cells (Fig. 2C). In contrast, when IFNg production by these T cells was measured, DC 
cultured either with tumor cells that received no irradiation or necrotic tumor cells 
generated by repeated freeze-thawing, induced no IFNg production (Fig. 2D). DC co-
cultured with irradiated tumor cells were efficient in inducing IFNg production by 
these T cells. The experiments demonstrate that DC are able to present naturally-
expressed tumor antigens to T cells and that this process is significantly enhanced 
following tumor cell irradiation.    
 
The TLR4-MyD88 pathway contributes to antigen cross-presentation 
 Tumor antigen cross-presentation from tumor cells treated with chemotherapy, 
especially with anthracyclines, has been studied more extensively than that from 
irradiated tumor cells. However, it has been suggested that in both cases antigen 
cross-presentation depends on the TLR4-HMGB interaction and consequently patients 
with TLR4 polymorphism are unable to mount immune responses to tumor antigens 
(19). In order to study the role of TLR4-HMGB signalling in antigen cross-
presentation from irradiated tumor cells, we used an HMGB1 inhibitor (24) and 
measured the effect on antigen cross-presentation. The inhibitor was applied to tumor 
cells 1h before irradiation. A significant decrease in T cell IFNγ production was 
observed (Fig. 3Ai), however HMGB1 inhibition did not affect CD86 expression on 
DC after their co-culture with tumor cells (Fig 3Aii). As HMGB1 can bind to multiple 
receptors, such as TLR2 and TLR4, we also inhibited the MyD88/TRIF signalling 
pathway by applying inhibitory peptides and compared T cell stimulation results to 
those obtained with the membrane permeable control peptides. The optimum 
concentrations of the inhibitory peptides were established in LPS-induced 
TNFα production experiments (not shown). Based on the results, both peptides were 
used at 25 mM in the cross-presentation blocking experiments. While neither TRIF 
nor the MyD88 inhibitory peptide had any effect on their own (not shown), when 
applied together, they resulted in a small but significant inhibitory effect on antigen 
cross-presentation (Fig 3B).  
 
TLR4 polymorphism does not impact on antigen cross-presentation from 
irradiated tumor cells 
 In order to elucidate whether TLR4 SNP would have a detrimental effect in 
PCa patients receiving radiotherapy, due to impaired antigen cross-presentation (19) 
as shown with anthracycline treated tumor cells, we conducted a series of experiments 
with DC generated from monocytes of donors with the normal (Asp299) TLR4 allele 
(n=5) or with the allele carrying the Asp299Gly SNP (n=4). All donors were HLA-
A2
+
. The general characterisation of monocytes and DC revealed that TLR4 
expression levels were identical in both groups (Fig. 4Ai, ii) and LPS-activated 
TNFα production was also comparable in both group of donors (Fig 4B). We also 
established that phenotypic maturation of DC (CD86, HLA-DR and CD83), carrying 
the SNP allele, following co-culture with irradiated tumor cells was unimpaired (Fig. 
4B). However, the most relevant question was whether antigen cross-presentation by 
DC was affected in donors carrying the SNP allele. The results in Fig 4C show that 
cross-presentation of a naturally expressed tumor antigen from irradiated tumor cells 
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was similarly efficient by DC with the Asp299 or the Gly299 TLR4 allele, 
respectively.  
 Taken together, our results indicate that the TRIF/MyD88 signalling pathway 
and HMGB1 contribute to tumor antigen cross-presentation; however, we found no 
evidence that TLR4 polymorphism impairs antigen cross-presentation from irradiated 
tumor cells.  
 
Hsp70 inhibition has no effect on Hsp70 upregulation but blocks antigen cross-
presentation 
 As shown in Fig. 1E and F, Hsp70 is significantly upregulated in irradiated 
tumor cells. As the contribution of heat shock proteins to antigen cross-presentation in 
other systems has been well demonstrated, we carried out experiments to establish 
whether Hsp70 plays an important role in cross-presentation of irradiated tumor cells. 
To test this we used the novel small molecule inhibitor, VER155008, which inhibits 
the activity of both the induced and the constitutive form of Hsp70 via binding to the 
ATPase pocket and allosterically preventing substrate binding (25, 26). VER155008 
treatment of tumor cells has been shown to inhibit tumor cell growth and induce 
tumor cell death. We applied this inhibitor to tumor cells before irradiation and for the 
72h culture preceding their co-culture with DC. Tumor cell numbers after 72h were 
only 18% lower when VER155008 was applied to irradiated tumor cells, presumably 
because tumor cell proliferation was already slowed down by the radiation. However, 
as expected, it inhibited the growth of unirradiated tumor cells by ~70% (Fig. 5A). 
Similarly, VER155008 significantly increased cell death of unirradiated DU145 cells 
(Fig. 5B). However, the inhibitor did not affect Hsp70 cell surface upregulation on 
irradiated tumor cells (Fig 5C). After establishing that VER155008 delivers the 
expected effects to otherwise un-manipulated tumor cells, we studied the effect on the 
ability of irradiated tumor cells to upregulate CD86 on DC (Fig. 5C) following a 24h 
co-culture of DC and DU145 cells. We found that CD86 upregulation failed on DC 
when they encountered VER155008-treated irradiated tumor cells (Fig. 5D). Finally, 
we applied VER155008 in the cross-presentation model described earlier. 
VER155008 significantly decreased both the background level cross-presentation of 
tumor antigen from non-irradiated tumor cells and the enhanced level of cross-
presentation observed from irradiated tumor cells (Fig 5E). This experiment provides 
strong evidence that Hsp70 plays an important role in tumor antigen cross-
presentation following irradiation.  
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Discussion 
 
Antigen cross-presentation has been indicated as an important mechanism for 
generating CD8
+
 T cell responses against solid tumors which do not migrate into 
lymph nodes or viruses which do not infect professional antigen presenting cells. 
While chemotherapy-induced antigen cross-presentation has been studied extensively, 
there is a paucity of information about ionizing radiation-mediated antigen cross-
presentation. The abscopal effect, observed in patients undergoing radiation therapy, 
has been demonstrated to be immune mediated and is likely to involve antigen cross-
presentation from irradiated tumors (4, 5). Further studies in this field would aid 
better understanding of how radiation therapy could be made more successful.  
 Our study addresses the mechanistic details of antigen cross-presentation from 
irradiated human tumor cells. We established a model using a tumor-specific T cell 
line as a detector of cross-presentation of a naturally expressed tumor antigen from 
irradiated, HLA-mismatched PCa tumor cells. The radiation dose (12 Gy) used in 
these experiments is in line with the latest technical developments of radiation therapy 
in prostate cancer and other malignancies. High dose brachytherapy and intensity 
modulated radiotherapy offer treatments with fewer fractions but higher doses, 
delivered more precisely to the cancer (27). The cellular effect of radiation is 
complex, resulting in growth arrest, senescence and different types of cell death. We 
observed cell cycle arrest at the G2/M phase, as reported by others (28), and a gradual 
increase of cell death with time following radiation. Cell death was predominantly of 
late apoptotic/necrotic type. The p53 gene is mutated in DU145 cells, which may 
impact on radiation-mediated repair response and apoptosis (29). As p53 mutations 
are frequent in PCa (30), our observations are likely to be representative of the 
physiological behaviour of the majority of prostate cancer cells. 
 Radiation-induced upregulation of CRT from the endoplasmic reticulum to the 
cell surface is one of the typical stress responses with an important immunological 
impact, such as the facilitation of phagocytosis (31). The results show a partial 
contribution by the TLR signalling pathway and HMGB1 to antigen cross-
presentation. HMGB1 is both a nuclear factor and a secreted protein. In the nucleus, it 
acts as an architectural chromatin-binding factor that influences DNA tertiary 
structure (32). When released from dying cells, it functions as a pro-inflammatory 
cytokine (33). However, its effects are pleiotropic and they depend not only on its 
redox status but also on the particular receptor it binds, such as RAGE, TLR2 or 
TLR4. Glycyrrhizin, which binds directly to HMGB1 and inhibits its chemokine 
function and autophagy induction (34, 35) among other potential effects, was proved 
inhibitory in the cross-presentation model, but did not inhibit DC activation. This 
indicates that HMGB1’s role in antigen cross-presentation does not depend on its 
cytokine-like function.  
 HMGB1 has been shown to associate with TLR4 (36). The Asp299Gly SNP 
of TLR4 causes structural changes of the TLR4 extracellular domain, with a potential 
impact on LPS binding (37), while cross-presentation was implied to be affected as 
well, similar to that observed in TLR4
-/- 
knockout mice (19). However, LPS-induced 
cytokine production is not affected by this TLR4 SNP, even when the SNP is present 
in a homozygous form (38). Our experiments confirmed that LPS-induced TNFα-
production is not affected by the Asp299Gly SNP in DC but, unlike in the 
anthracycline-induced cross-presentation model (19), we observed no impact by the 
SNP on antigen cross-presentation either. Our DC were heterozygous for the SNP 
allele thus functionally not comparable to the TLR4
-/-
 mouse DC. However, there is a 
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discrepancy between the DC results by Apetoh et al. (19) and that observed by us; this 
maybe due to differences between tumour cell responses to chemotherapy vs. 
radiation, or that TLR4 SNP has an impact on tumor responses via mechanisms other 
than antigen cross-presentation.  
 Removing the supernatant from irradiated DU145 cells before co-culturing 
them with DC reduced T cell activation but had no effect on DC maturation (not 
shown), indicating that both cell-associated and soluble factors are needed for 
efficient antigen cross-presentation from irradiated tumour cells. Another damage 
associated molecule group, upregulated by irradiation and released into the 
extracellular space, is heat shock proteins. We studied Hsp70 in detail in this paper as 
it has an important and well-documented function of chaperoning antigen when 
released from stressed or necrotic cells (39). Hsp70 levels are variable in PCa but 
generally higher in cancer tissue than in non-malignant prostate tissue (40). Irradiation 
induces upregulation of Hsp70 gene expression in PCa cells as a means of protection 
from radiation (41). We observed increased cytosolic and surface Hsp70 levels upon 
irradiation in DU145 cells. The molecular chaperone activity of Hsp70 is conferred by 
two functional domains: a peptide-binding and an ATP-binding domain. One domain 
reciprocally affects the other, and when polypeptides bind to the peptide-binding 
domain, ATP is hydrolysed to ADP but when ATP binds, the polypeptides dissociate 
(42). As ATP levels usually drop in irradiated cells, protein binding by ADP-
associated Hsp70 is likely to become a relatively stable association, linking stress-
response with chaperoning function. VER155008, a novel and highly specific Hsp70 
family inhibitor, functions as an ATP mimetic and binds to the ATPase pocket of 
Hsp70 (43), thereby inhibiting the activity of Hsp70. Thus, in our model, its effect in 
inhibiting antigen cross-presentation can be explained by the inability of Hsp70 to 
remain associated with polypeptides.  
 Hsp70 can bind to TLR2/TLR4, CD91 or CD40 and to scavenger receptors 
such as SREC-I and LOX-1. As Hsp70 can bind directly to TLR4 as one of its 
potential receptors and upregulate HMGB1 (44) in DC, there is a possibility for cross-
talk between Hsp70 and the HMGB/TLR4 pathways. On the other hand, SREC-I and 
LOX-1 were each responsible for about 50% of antigen cross-presentation in a murine 
system (17). Hsp70 uptake and the subsequent intracellular events in DC are subjects 
of ongoing studies in our laboratory. 
  Despite the growing list of players for the “ideal” antigen cross-presentation, 
the plasticity of the process has also been demonstrated, as e.g. highly polarized (type-
1) DC can efficiently prime T cells even when co-cultured with apoptotic cells (45). 
Furthermore, DC can acquire antigen from live cells for antigen cross-presentation 
both in tumor and viral settings (46-48). In the latter, while apoptosis of infected 
fibroblasts is inhibited by the virus, Hsp70 expression is significantly upregulated by 
the infection (49). These examples illustrate that if any key player of the antigen-
cross-presentation process is overexpressed or hyper-activated, it can generate a 
shortcut leading to antigen cross-presentation even if not all the elements, as 
discussed earlier, are present.    
 Taken together, our study provides strong evidence that pre-existing tumor 
antigen-specific T cells can be re-activated as a consequence of high dose radiation. 
We also demonstrate the crucial role that Hsp70 plays in antigen cross-presentation 
from irradiated tumor cells. These observations have practical implications in the 
design of future immuno-radiotherapy combinations. 
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Figure Legends 
 
Figure 1. Radiation causes cell cycle arrest, cell death and changes to key 
immunologically relevant molecules in prostate cancer cells. A, Cell cycle analysis of 
DU145 cells irradiated with increasing dose (x-axis) and incubated for 4, 24 or 48h as 
indicated above the graphs. Means±SEM of cells from triplicate cultures in different 
cell cycle phases are shown as indicated. B, Percentage of DU145 cells labelled with 
Annexin and Propidium iodide (PI), respectively, following 12Gy radiation and 
cultured up to 72h (x-axis) is shown from triplicates (mean+SEM). C, Medium 
fluorescence intensity (mfi) of 5T4 expression in fixed and permeabilized DU145 
cells 48h following irradiation from triplicate cultures (Mean+SEM). D, Mfi of 
HMGB1 in DU145 cells (total staining in fixed and permeabilized cells) at different 
times after 12 Gy irradiation (x-axis) from triplicate cultures (Mean+SEM). E, Hsp70-
FITC (green) and DAPI (blue) labelled DU145 cells 72h after 0Gy (left) or 12Gy 
(right) irradiation. 63x magnification (Axiovert-40, Zeiss). F, Representative dot plots 
of DU145 cells 72h after 0Gy or 12Gy radiation showing CRT (x-axis) and Hsp70 (y-
axis) co-expression or isotype control (first panel). The numbers show Hsp70 single 
positive (upper left) or Hsp70+CRT+ double positive cells (right quadrant). All 
experiments were repeated at least three times.   
Figure 2. Irradiated tumor cells are taken up by DC and trigger DC maturation and 
antigen cross-presentation. A, Representative dot plot showing uptake of CFSE-pre-
labelled DU145 cells (x-axis) after 0Gy (i) or 12Gy (ii) irradiation by DC. The latter 
were identified by HLA-DR staining. Phagocytic DC are cells in the upper right 
quadrant. iii. Summary of results from triplicates, mean+SEM are shown. B, flow 
cytometry analysis of DC markers after 24h co-culture with 0Gy or 12Gy irradiated 
DU145 cells, as indicated. Mean+SEM of mfi from triplicate cultures are shown. C, 
Proliferation of CFSE-labeled 5T4-specific T cells 5 days after stimulation by 
autologous DC co-cultured with DU145 cells, as indicated. Mean+SEM of CFSE mfi 
from triplicate cultures are shown. D, 5T4-specific T cells were stimulated overnight 
with DC co-cultured with DU145 cells as shown (FT=freeze-thawed). IFNγ+ T cells 
were defined by flow cytometry using intracellular cytokine staining. Mean+SEM of 
% IFNγ+ T cells from triplicate cultures are shown. All experiments were repeated at 
least three times.   
 
Figure 3. The effect of HMGB1/TLR4 pathway inhibitors on DC maturation and 
antigen cross-presentation. A, DC were co-cultured with 0Gy or 12Gy treated DU145 
cells in the presence or absence of 50 µM HMGB1 inhibitor (Glycyrrhizin) as 
indicated for 72h. 5T4-specific T cell stimulation as described for the cross-
presentation assay (i) and CD86 upregulation on DC (ii) were analyzed by flow 
cytometry. The columns show mean+SEM of results from triplicate cultures. B, DC 
were cultured as in A, but in the presence of 25 µg/ml MyD88 and 25 µg/ml TRIF 
inhibitory peptides together (inhibitory) or of the same concentration of control 
peptide. Mean+SEM of % IFNγ+ T cells from triplicate cultures are shown. The 
experiments were repeated 2-3 times.   
 
Figure 4. TLR4 polymorphism does not affect cross-presentation. A, i, TLR4 
expression on monocytes from 5 donors with the Asp299 TLR4 allele (299A) and 4 
donors with the Gly299 (299G) allele are shown; ii, as in i, expression is shown on 
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day 5 DC.  iii, day 5 DC were stimulated with LPS and TNFα production measured 
by flow cytometry. Symbols represent % positive cells from individual donors. The 
boxes show the 25% and 75% percentiles of the combined data, the lines in the boxes 
show the median values. B, DC phenotyping from the donors as in A. Each line 
represent an individual donor. C, Stimulation of 5T4-specific T cells with DC, from 
donors as in A, loaded with 0Gy or 12Gy irradiated DU145 cells. Symbols represent 
means of triplicate results, each line represents an individual donor.    
 
Figure 5. Hsp70 inhibitor VER155008 prevents DC maturation and antigen cross-
presentation. A-C, The effects of VER155008 on DU145 cells during 72h post-
irradiation culture. Mean+SEM of results from triplicate samples are shown. A, the 
effect on cell numbers expressed as % of cell numbers in the absence of the inhibitor; 
B, Annexin
+
PI
+
 cell frequencies as determined by flow cytometry; C, surface 
expression of Hsp70. D-E, The effect of VER155008-treated or untreated DU145 
cells on DC; D, CD86 expression following 24h coculture of DU145 cells with DC; 
E, stimulation of 5T4-specific T cells in a cross-presentation experiment. The 
experiments were repeated 2-3 times.    





